在患有 Paroxysmal 夜间血红蛋白尿症的经验丰富的患者中,Pegcetacoplan 改善了铁过载
Jamile Shammo1, Peter Hillmen2, Peter Blandino2
1Feinberg School of Medicine, Northwestern University, Chicago, IL 60612, USA.
International journal of molecular sciences
|October 29, 2025
概括
佩格塞塔科普兰治疗通过减少血液溶解和贫血,改善了性夜间血红蛋白尿症 (PNH) 患者的铁过载. 这种疗法还降低了输血需求,并使网细胞数量正常化,这表明铁的调节更好.
科学领域:
- 血液学 血液学 血液学
- 药理学 药理学是指药理学的学科.
背景情况:
- 用补充因子5 (C5) 抑制剂治疗阴性夜间血红 (PNH) 可能导致铁过载.
- 这种过载是由于持续的血管内血液溶解 (IVH) 和新兴的血管外血液溶解 (EVH) 造成的.
研究的目的:
- 为了评估基科普兰对PNH患者铁调节的影响.
- 在PEGASUS试验中分析输血相关数据和铁生物标志物.
主要方法:
- 对PEGASUS第三阶段试验 (NCT03500549) 的后期分析.
- 患有PNH和残留性贫血的患者接受了eculizumab和pegcetacoplan,然后随机选择单一治疗.
- 评估了铁过载状态和生物标志物 (黑皮丁,费里丁,转蛋白和度,绝对网红细胞计数).
主要成果:
- 铁过载在72.7%的接受佩格塞塔科普兰治疗的患者中消失.
- 佩格塞塔科普兰降低了铁过载和没有铁过载的患者的输血需求.
- 肝素度增加,绝对网细胞计数 (ARC) 降至正常范围.
结论:
- 佩格塞塔科普兰有效地管理PNH患者的铁过载.
- 该药物通过抑制IVH和EVH来改善铁的调节,从而预防贫血.
- 佩格塞塔科普兰对关键的铁相关生物标志物产生积极影响.
相关概念视频
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
429
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
429
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
452
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
452
01:29Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
308
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
308
01:20Antiepileptic Drugs: Potassium Channel Activators
624
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
624